JUN 23, 2017 08:23 PM PDT

Delivering A New HIV Vaccine

WRITTEN BY: Kara Marker

Creating a successful vaccine for HIV has so far been unsuccessful, but now scientists are zeroing in on two important factors for perfecting the vaccine: timing and mode of delivery.

The vaccine candidates used in the study mimic the trimeric envelope protein spikes on the surface of HIV. Rendering of HIV with envelope protein trimers clearly visible on the virus surface. Credit: La Jolla Institute for Allergy and Immunology

The potential HIV vaccine is based on neutralizing antibodies, which attach to viruses and prevent them from promoting infection. However, in the past neutralizing antibodies have been “notoriously difficult” to create in the context of targeting HIV. From the La Jolla Institute for Allergy and Immunology, researchers tested the efficacy of an optimized vaccine in non-human primates, a traditional model for studying HIV. However, the initial vaccine wasn’t successful at first.

"The animals' immune responses, although the right kind, weren't very robust and a few didn't respond at all," explained Colin Havenar-Daughton, PhD. "That caused significant concern that the immunogen wouldn't consistently trigger an effective immune response in all individuals in a human clinical trial."

They improved upon the vaccine, using subcutaneous delivery - under the skin like insulin and morphine injections. Additionally, they increased the time intervals between immunizations, ensuring a slow and steady delivery. This makes the vaccine’s effect stronger, activating the neutralizing antibodies.

"Depending on how we gave the vaccine, there was a bigger difference due to immunization route than we would have predicted," explained co-lead author Matthias Pauthner. "We can help translate what we know now into the clinic."

HIV in 2017

HIV is now relatively considered to be a “chronic, manageable disease” thanks to antiretroviral drugs that treat AIDS. Although, accessibility to these drugs isn’t guaranteed; only half of people living with HIV have access to treatment, and new people are contracting the disease every day. The new

"The vaccine candidates we worked with here are probably the most promising prototypes out there, and one will go into people in 2018," said Professor Dennis R. Burton, PhD.

The present study was published in the journal Immunity.

 

Source: La Jolla Institute for Allergy and Immunology, Healthline

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
OCT 16, 2018
Drug Discovery
OCT 16, 2018
Potential Targeted Treatment for Crohn Disease
Emerging as a global disease with rates increasing the past 5 decades, Crohn’s disease (CD) is the chronic inflammation of the intestinal tract. Now,...
OCT 31, 2018
Drug Discovery
OCT 31, 2018
New Drug Target For a Rare Lymphoma
The promise of immunotherapy in oncology is stronger than ever. Now, an international team of scientists and physicians from the Research Institute of the ...
NOV 20, 2018
Immunology
NOV 20, 2018
Mutations Mutations Which Ones Do We Want?
A team at UCSF makes use of new SLICE tool to generate mutations that reveal specific genetic functions....
NOV 28, 2018
Immunology
NOV 28, 2018
Regulators to the Rescue
Scientists at Scripps Research Institute describe the nature of an immune regulator protein...
DEC 05, 2018
Immunology
DEC 05, 2018
Combo-Kick to Battle Lymphoma
Combination immunotherapy has provided remission for patients suffering from Hodgkin's Lymphoma...
JAN 15, 2019
Immunology
JAN 15, 2019
Unconventional T Cells
Spondyloarthritis is one of the most common types of chronic joint inflammation affecting nearly 1-2 percent of the Western population. Scientists report that rare populations of unconvention...
Loading Comments...